搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
GlobalData on MSN
18 小时
FDA approves Pfizer’s HYMPAVZI to treat haemophilia
HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.
3 天
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...
1 小时
辉瑞新药HYMPAVZI获美国FDA批准用于治疗血友病
10月15日,辉瑞制药宣布,HYMPAVZI ...
Zacks.com on MSN
17 小时
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
Medscape
3 天
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
3 小时
辉瑞新药HYMPAVZI获美国FDA批准用于治疗血友病A及血友病B
10月15日,辉瑞制药宣布,HYMPAVZI™(马塔西单抗/marstacimab-hncq)近日获美国食品药品监督管理局(FDA)批准,用于规律性治疗不伴凝血因子抑制物的血友病A(先天性凝血VIII因子缺乏症)或血友病B(先天性凝血IX因子缺乏症)的12岁以上患者,以减少出血的发作。HYMPAVZI是辉瑞今年获得FDA批准的第二款血友病治疗药物。
18 小时
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
The Financial Express
1 天
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
The FDA granted the approval of Hympavzi to Pfizer Inc.
Managed Healthcare Executive
3 天
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
3 天
on MSN
Pfizer gets FDA approval for Hympavzi for hemophilia
Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency ...
来自MSN
3 小时
辉瑞「HYMPAVZI™」获FDA批准上市,用于血友病A、B
10月15日,辉瑞官微发布消息称,期创新药物HYMPAVZI™(马塔西单抗/marstacimab-hncq)获美国食品药品监督管理局(FDA)批准,用于规律性治疗不伴凝血因子抑制物的血友病A(先天性凝血VIII因子缺乏症)或血友病 ...
hemophilianewstoday
3 天
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈